Recorded Third Quarter Revenue of $33.8 Million Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million Celebrated Completion of Recent Expansion Program with Grand Opening of Cell and Gene Therapy Manufacturing Facility in January 2024 Completed Convertible Debt Offering Subsequent to Quarter End, Extending Debt Maturity to 2029 TUSTIN, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Avid... Read More